Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

28.90
-1.0500-3.51%
Post-market: 28.900.00000.00%17:57 EDT
Volume:909.35K
Turnover:26.36M
Market Cap:1.66B
PE:-12.79
High:30.46
Open:29.62
Low:28.37
Close:29.95
52wk High:40.37
52wk Low:4.30
Shares:57.37M
Float Shares:48.42M
Volume Ratio:0.46
T/O Rate:1.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2601
EPS(LYR):-2.2601
ROE:-46.56%
ROA:-25.68%
PB:5.42
PE(LYR):-12.79

Loading ...

Roth MKM Keeps Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 20

Capricor Therapeutics Nears Key Milestones After Earnings Call

TIPRANKS
·
Mar 14

Capricor selloff today a buying opportunity, says Roth Capital

TIPRANKS
·
Mar 14

Alliance Global Partners Keeps Their Buy Rating on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 14

Capricor Therapeutics Inc : B. Riley Raises Target Price to $63 From $50

THOMSON REUTERS
·
Mar 13

B. Riley Adjusts Price Target on Capricor Therapeutics to $63 From $50, Maintains Buy Rating

MT Newswires Live
·
Mar 13

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 13

Capricor Therapeutics Q4 Loss Widens

MT Newswires Live
·
Mar 13

Earnings Flash (CAPR) Capricor Therapeutics Posts Q4 Loss $-0.62, vs. FactSet Est of Loss of $-0.55

MT Newswires Live
·
Mar 13

Capricor announces additional analyses, outcomes from Phase 3 HOPE-3 trial

TIPRANKS
·
Mar 12

Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy

GlobeNewswire
·
Mar 12

Roth MKM Remains a Buy on Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Capricor Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
Mar 11

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

MT Newswires Live
·
Mar 11

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 10

Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review

Benzinga_recent_news
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Capricor Therapeutics (CAPR)

TIPRANKS
·
Mar 10

BUZZ-Capricor surges as FDA resumes review of muscle‑wasting disease drug

Reuters
·
Mar 10

Capricor announces establishment of new PDUFA date for dermiocel BLA

TIPRANKS
·
Mar 10